A non-invasive screening method for colorectal cancer
based on blood cfDNA methylation characteristics
Molecular Cancer (2023) 22:157
https://doi.org/10.1186/s12943-023-01866-z
https://doi.org/10.1186/s12943-023-01866-z
Abstract
Background Although colonoscopy is the standard screening test for colorectal cancer (CRC), its use is limited by a poor compliance rate, the need for extensive bowel preparation, and the risk of complications. As an alternative, an FDA-approved stool-based DNA test, Cologuard, has demonstrated satisfactory detection performance for CRC, but its compliance rate remains suboptimal, primarily attributable to individuals’ reluctance to provide stool samples.
Methods We developed a noninvasive blood-based CRC test, ColonSecure, based on cell-free DNA containing cancer-specific CpG island methylation patterns. We initially screened publicly available datasets for differentially methylated CpG sites in CRC with prediction potential. Subsequently, we performed two sequential bisulfite-free methylation sequencing on blood samples obtained from CRC patients and non-cancer controls. Through rigorous evaluation of each marker and machine learning-assisted feature selection, we identified 149 hypermethylated markers from over 193,000 CpG sites. These markers were then utilized to construct the ColonSecure model, enabling
accurate CRC detection.
Results We validated the efficacy of our cell-free DNA methylation-based blood test for CRC screening with 3493 high-risk individuals identified from 114,136 urban residents. The ColonSecure test identified 89 out of 103 CRC patients diagnosed by the follow-up colonoscopy, outperforming CEA, CRP, and CA19-9 (with a sensitivity of 86.4% compared to 45.6%, 39.8%, and 25.2% for CEA, CRP, and CA19-9 respectively; an AUROC of 0.956 compared
to an AUROC of < 0.77 for other methods).
Conclusion Our observations emphasize the potential of our multiple cfDNA methylation marker-based test for CRC screening in high-risk populations.
Keywords Cell-free DNA, Hypermethylation, Colorectal cancer, Prospective validation, Populational screening
For details, please visit：https://link.springer.com/article/10.1186/s12943-023-01866-z
Magen has devleoped a whole solution for Cell free DNA extraction, including cfDNA/RNA extraction kits, magnetic beads and automated extraction systems.
Please visit https://www.magen-tec.com/Cancer/index.aspx